This Article Full Text Full Text (PDF) Online Supplement All Versions of this Article: 200308-1142OCv1 170/4/360    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leuchte, H. H. Articles by Behr, J. Search for Related Content PubMed PubMed Citation Articles by Leuchte, H. H. Articles by Behr, J.

Brain Natriuretic Peptide and Exercise Capacity in Lung Fibrosis and Pulmonary Hypertension

Division of Pulmonary Diseases, Department of Internal Medicine I, Ludwig Maximilians University, Klinikum Grosshadern, Munich, Germany

Correspondence and requests for reprints should be addressed to Hanno H. Leuchte, M.D., Division of Pulmonary Diseases, Department of Internal Medicine I, Ludwig Maximilians University, Klinikum Grosshadern, Munich Marchioninistr. 15, 81377 Munich, Germany. E-mail: hleuchte{at}med.uni-muenchen.de

Pulmonary hypertension (PH) can develop in lung fibrosis, and contributes to increased morbidity and mortality. Noninvasive parameters in the evaluation of PH in lung disease could aid in the management of these subjects. In this study, we aimed to characterize the role of brain natriuretic peptide (BNP) and the six-minute walk distance (6-MWD) in the assessment of pulmonary hypertension (PH) in subjects with lung fibrosis. Subjects with lung fibrosis and elevated BNP levels (n = 20) had significantly more severe PH during right heart catheterization than those with lung fibrosis, and normal BNP levels (mean pulmonary arterial pressure (40.85 ± 3.2 mm Hg vs. 23.42±1.44 mm Hg, respectively) (n = 19) (p < 0.001). Significant correlations between lung volumes and BNP concentrations were not observed. A weak correlation existed between capillary pO₂ and 6-MWD (r = 0.42; p < 0.001). The presence of moderate–severe PH was associated with significant reduction of the 6-MWD. BNP concentrations predicted moderate–severe PH with 100% sensitivity and high specificity (89%). We conclude that BNP is an excellent marker for the presence of PH in patients with lung fibrosis. In addition, our data suggest that PH contributes significantly to exercise limitation in patients with severe lung fibrosis, raising the possibility that treatment of PH may be beneficial in these patients.

Key Words: natriuretic peptide, brain • hypertension • pulmonary • fibrosis

This article has been cited by other articles:

				V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1573 - 1619. [Full Text] [PDF]

				Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association Circulation, April 28, 2009; 119(16): 2250 - 2294. [Full Text] [PDF]

				A U Wells, N Hirani, and on behalf of the BTS Interstitial Lung Disease Gui Interstitial lung disease guideline Thorax, September 1, 2008; 63(Suppl_5): v1 - v58. [Full Text] [PDF]

				G. Warwick, P. S. Thomas, and D. H. Yates Biomarkers in pulmonary hypertension Eur. Respir. J., August 1, 2008; 32(2): 503 - 512. [Abstract] [Full Text] [PDF]

				J. Behr and J. H. Ryu Pulmonary hypertension in interstitial lung disease Eur. Respir. J., June 1, 2008; 31(6): 1357 - 1367. [Abstract] [Full Text] [PDF]

				A. Mekontso Dessap, R. Leon, A. Habibi, R. Nzouakou, F. Roudot-Thoraval, S. Adnot, B. Godeau, F. Galacteros, C. Brun-Buisson, L. Brochard, et al. Pulmonary Hypertension and Cor Pulmonale during Severe Acute Chest Syndrome in Sickle Cell Disease Am. J. Respir. Crit. Care Med., March 15, 2008; 177(6): 646 - 653. [Abstract] [Full Text] [PDF]

				D. A. Zisman, A. S. Karlamangla, S. M. Kawut, O. A. Shlobin, R. Saggar, D. J. Ross, M. I. Schwarz, J. A. Belperio, A. Ardehali, J. P. Lynch III, et al. Validation of a Method To Screen for Pulmonary Hypertension in Advanced Idiopathic Pulmonary Fibrosis Chest, March 1, 2008; 133(3): 640 - 645. [Abstract] [Full Text] [PDF]

				M. K. Han, V. V. McLaughlin, G. J. Criner, and F. J. Martinez Pulmonary Diseases and the Heart Circulation, December 18, 2007; 116(25): 2992 - 3005. [Abstract] [Full Text] [PDF]

				A. F. Shorr, J. L. Wainright, C. S. Cors, C. J. Lettieri, and S. D. Nathan Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant Eur. Respir. J., October 1, 2007; 30(4): 715 - 721. [Abstract] [Full Text] [PDF]

				N. M. Patel, D. J. Lederer, A. C. Borczuk, and S. M. Kawut Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis Chest, September 1, 2007; 132(3): 998 - 1006. [Abstract] [Full Text] [PDF]

				I. Noth and F. J. Martinez Recent Advances in Idiopathic Pulmonary Fibrosis Chest, August 1, 2007; 132(2): 637 - 650. [Abstract] [Full Text] [PDF]

				R. P. Baughman, B. K. Sparkman, and E. E. Lower Six-Minute Walk Test and Health Status Assessment in Sarcoidosis Chest, July 1, 2007; 132(1): 207 - 213. [Abstract] [Full Text] [PDF]

				S. D. Nathan, P. W. Noble, and R. M. Tuder Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension: Connecting the Dots Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 875 - 880. [Abstract] [Full Text] [PDF]

				C. D. Fell and F. J. Martinez The Impact of Pulmonary Arterial Hypertension on Idiopathic Pulmonary Fibrosis Chest, March 1, 2007; 131(3): 641 - 643. [Full Text] [PDF]

				K. Hamada, S. Nagai, S. Tanaka, T. Handa, M. Shigematsu, T. Nagao, M. Mishima, M. Kitaichi, and T. Izumi Significance of Pulmonary Arterial Pressure and Diffusion Capacity of the Lung as Prognosticator in Patients With Idiopathic Pulmonary Fibrosis Chest, March 1, 2007; 131(3): 650 - 656. [Abstract] [Full Text] [PDF]

				J. H. Ryu, M. J. Krowka, K. L. Swanson, P. A. Pellikka, and M. D. McGoon Pulmonary Hypertension in Patients With Interstitial Lung Diseases Mayo Clin. Proc., March 1, 2007; 82(3): 342 - 350. [Abstract] [Full Text] [PDF]

				H. Liu, L. Liu, B. S. Fletcher, and G. A. Visner Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis FASEB J, November 1, 2006; 20(13): 2384 - 2386. [Abstract] [Full Text] [PDF]

				H. A. Ghofrani, R. Voswinckel, F. Reichenberger, N. Weissmann, R. T. Schermuly, W. Seeger, and F. Grimminger Hypoxia- and non-hypoxia-related pulmonary hypertension - Established and new therapies Cardiovasc Res, October 1, 2006; 72(1): 30 - 40. [Abstract] [Full Text] [PDF]

				R. F. Machado, A. Anthi, M. H. Steinberg, D. Bonds, V. Sachdev, G. J. Kato, A. M. Taveira-DaSilva, S. K. Ballas, W. Blackwelder, X. Xu, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA, July 19, 2006; 296(3): 310 - 318. [Abstract] [Full Text] [PDF]

				M. H. Williams, C. E. Handler, R. Akram, C. J. Smith, C. Das, J. Smee, D. Nair, C. P. Denton, C. M. Black, and J. G. Coghlan Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension Eur. Heart J., June 2, 2006; 27(12): 1485 - 1494. [Abstract] [Full Text] [PDF]

				H. H. Leuchte, R. A. Baumgartner, M. E. Nounou, M. Vogeser, C. Neurohr, M. Trautnitz, and J. Behr Brain Natriuretic Peptide Is a Prognostic Parameter in Chronic Lung Disease Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 744 - 750. [Abstract] [Full Text] [PDF]

				C. J. Lettieri, S. D. Nathan, S. D. Barnett, S. Ahmad, and A. F. Shorr Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis Chest, March 1, 2006; 129(3): 746 - 752. [Abstract] [Full Text] [PDF]

				A. Clerico, F. A. Recchia, C. Passino, and M. Emdin Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H17 - H29. [Abstract] [Full Text] [PDF]

				C. Strange Treatment for Secondary Pulmonary Hypertension Chest, October 1, 2005; 128(4): 1897 - 1898. [Full Text] [PDF]

				H. F. Nadrous, P. A. Pellikka, M. J. Krowka, K. L. Swanson, N. Chaowalit, P. A. Decker, and J. H. Ryu Pulmonary Hypertension in Patients With Idiopathic Pulmonary Fibrosis Chest, October 1, 2005; 128(4): 2393 - 2399. [Abstract] [Full Text] [PDF]

				M. Mockel, R. Muller, J. O. Vollert, C. Muller, A. Carl, D. Peetz, F. Post, J. K. Kohse, and K. J. Lackner Role of N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification in Patients Presenting in the Emergency Room Clin. Chem., September 1, 2005; 51(9): 1624 - 1631. [Abstract] [Full Text] [PDF]

				T. D. Bradley, Y. E. Miller, F. J. Martinez, D. C. Angus, W. MacNee, and E. Abraham Interstitial Lung Disease, Lung Cancer, Lung Transplantation, Pulmonary Vascular Disorders, and Sleep-disordered Breathing in AJRCCM in 2004 Am. J. Respir. Crit. Care Med., April 1, 2005; 171(7): 675 - 685. [Full Text] [PDF]

				N. S. Hill Brain Natriuretic Peptide: Is It Helpful in Detecting Pulmonary Hypertension in Fibrotic Lung Disease? Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 352 - 353. [Full Text] [PDF]